TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: 13-valent Pneumococcal Conjugate Vaccine Study in Adults => 50 Years of Age in Mexico

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female older than 50 years of age~* Eligibility must be determined by medical history, physical exam and clinical judgment~* Able to complete an electronic diary~* Available for duration of study~* Negative pregnancy test for subjects in group 2 age 50 to 64 years~* Practice abstinence or use reliable birth control if age is 50 to 64 years~Exclusion Criteria:~* History of allergic reaction to any vaccine~* Previous vaccination with licensed or experimental pneumococcal vaccine~* S. pneumonia infection within past 5 years before investigational product administration~* Known or suspected immunodeficiency or received treatment including cytotoxic agents or systemic corticosteroids, serious chronic disorder such as malignancy cancer~* Receipt of plasma products or immunoglobulins within 60 days~* Bleeding conditions or diathesis~* Receipt of investigational product within 28 days before study entry~* Other severe acute or chronic medical or psychiatric condition

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): =\> 65 years of age
- Group 2 (Type: EXPERIMENTAL): 50 to 64 years of age

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BP-C1 in Short-term Treatment of Patients With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Female patients with histologically verified metastatic breast cancer (stage IV) with measurable metastases, between 18 and 80 years of age, who had undergone at least three lines of chemotherapy and had an expected survival time of at least 3 months.~Exclusion criteria:~Patients fulfilling at least one of the following criteria will be excluded from participation in the study:~* Abnormal liver function classified as total bilirubin \>34 μmol/L or ALAT \> 3 times of the upper limit of normal (ULN). In case of metastases in the liver, the ALAT limit for exclusion is set to 5хULN.~* Abnormal kidney function defined by serum creatinine \>120 μmol/L.~* Abnormal coagulation capacity defined by the relative arbitrary concentration of coagulation factors 2,7,10; INR \>1.5.~* Verified metastases to the brain.~* Synchronous cancer except for non-melanoma skin cancer and early stage of cervical cancer.~* Abnormal hematology status defined by hemoglobin \< 9.0 g/dL, platelet count \< 100,000/mm\^3 or leucocytes \< 3 x 10\^9/L.~* Clinically significant abnormal ECG.~* Karnofsky performance status score \<60%.~* Pregnant or breast feeding women.~* Women of fertile age who do not want to be tested for possible pregnancy.~* Fertile female who do not want to use safe protection against pregnancy, starting one month before the start of the study treatment and lasting at least six weeks after.~* Uncontrolled bacterial, viral, fungal or parasite infection.~* Under systemic treatment with corticosteroids or other immunosuppressive drugs in the last 21 days before start of the trial treatment.~* Participating in another clinical trial with pharmaceuticals in the last six weeks before start of this trial treatment.~* Not able to understand information.~* Not willing or not able to give written consent to participate in the study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- BP-C1 (Type: EXPERIMENTAL): Patients randomized to BP-C1 arm will be treated for 32 consecutive days. Patients who respond to treatment and do not experience untolerated toxicity are invited to participate in the BMC2011-02 study, where they will be offered to continue treatment with BP-C1.
- Placebo (Type: PLACEBO_COMPARATOR): Patients randomized to Placebo arm will be treated for 32 consecutive days. Thereafter the patients will cross over to 32-day treatment with BP-C1. Patients who respond to treatment and do not experience untolerated toxicity are invited to participate in the BMC2011-02 study, where they will be offered to continue treatment with BP-C1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 10 and older~* Documented diagnosis of HAE, Type I or II~* Executed informed consent~* Presentation for treatment within 8 hours of patient recognition of moderate to severe HAE attack~Exclusion Criteria:~* Receipt of investigational drug or device, other than DX-88, within 30 days of treatment~* Receipt of non-investigational C1-INH (C1 esterase inhibitor) within 7 days of treatment~* Diagnostic of acquired angioedema, estrogen-dependent angioedema or drug induced angioedema~* Pregnancy or breastfeeding~* Patients who have received DX-88 within 7 days of presentation for dosing in the Double-blind Phase

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DX-88 (ecallantide) (Type: EXPERIMENTAL): DX-88 (ecallantide) 30 mg given as three 10 mg/mL subcutaneous injections.
- Placebo (Type: PLACEBO_COMPARATOR): Phosphate Buffer Saline (PBS), pH 7.0 given as 3 subcutaneous injections.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vaginal Estriol in Multiple Sclerosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Female patients with RRMS over the age of 40 to 65.~   * Being prescribed vaginal estriol to treat their urogenital symptoms such as frequency, urgency, incontinence and frequent urinary tract infections.~  * Patients that had underwent chemical or surgical hysterectomy.~2. Patients will continue their current disease modifying agent for MS during the trial.~Exclusion Criteria:~1. Patients with history of breast cancer, uterine or ovarian cancer.~2. Patients with progressive multiple sclerosis~3. Patients who are unable to undergo an MRI~4. Males~5. Patient is already on vaginal or oral or transdermal estrogens~6. Pregnant or breast-feeding patients~7. Patient taking sex hormones eg testosterone for libido~8. Patients taking DHEA or OTC related products that could influence the hormonal milieu.~9. Patient with prolapse uterus or conditions that would impact on transvaginal absorption of estriol

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- urogenital symptoms (Type: OTHER): To evaluate the efficiency of vaginal estriol, as a treatment for urogenital symptoms in female patients with RRMS.
- remyelination (Type: EXPERIMENTAL): To evaluate the potential role of vaginal estriol in re-myelination in RRMS patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must have chronic genotype 1 HCV infection with HCV RNA level \>= 5.0 log10 IU/mL~* Patient has never received treatment for HCV~* Patient must be willing to use contraceptive measures from the time of informed consent to 6 months after last dose of study medication~Exclusion Criteria:~* Co-infection with any other HCV genotype or co-infection with the human immunodeficiency virus (HIV)~* Diagnosed with hepatic cirrhosis or hepatic failure~* A medical condition which is a contraindication to pegIFN or ribavirin therapy~* History of, or any current medical condition which could impact the safety of the patient in the study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- TMC435 100 mg 12 Wks + PR 24/48 (Type: EXPERIMENTAL): Participants received TMC435 100 mg once daily with PegIFNα-2a and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 24. Treatment was stopped at Week 24 for participants who achieved HCV RNA \< 1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable HCV RNA at Week 12. All other participants continued PR until Week 48.
- PBO 12 Wks + PR 48 (Type: EXPERIMENTAL): Participants received placebo (PBO) once daily with PegIFNα-2a and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 48.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: High Volume Injection or Autologous Conditioned Plasma (ACP) in Chronic Achilles Tendinopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinically and ultrasound diagnosed unilateral midt-tendinous achilles tendinopathy~* Symptoms \> 3 month~* No steroid injections \< 6 month~* 60 males with BMI \<30 between 18-60 years.~Exclusion Criteria:~* Bilateral achilles tendinopathy~* Insertional tendinopathy~* Steroid injections \< 6 month~* Diabetes or cardiovascular disease~* Smoking~* Treatment with fluoroquinolones \< 6 month

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- High Volume injection (Type: ACTIVE_COMPARATOR): A total volume of 50 ml:~* 10 mls 0.5% bupivacaine hydrochloride and~* 20 mg of Depomedrol (hydrocortisone)~* 40 mls saline (NaCl) HVI is injected one time at baseline and thereafter the group received sham treatment at 2 weeks, 4 weeks and after 6 weeks.
- Autologous conditioned plasma (ACP) (Type: ACTIVE_COMPARATOR): Whole blood was drawn from the patients using arthrex system (total of 10 mls whole blood). After that the whole blood is spined for 5 minutes and ACP with platelets and growth factors is separated from the red and white blood cells (4 mls).~The ACP is injected 4 times (at baseline, 2 weeks, 4 weeks and after 6 weeks)
- Placebo (Type: SHAM_COMPARATOR): A few drops of saline is injected in the soft tissue away from the tendon.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of a Personalized Web-based Antenatal Care Planner

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* less than 28 weeks pregnant access to Internet~Exclusion Criteria:~* cannot speak/read English and no translator

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- personalized web prenatal information (Type: EXPERIMENTAL): Personalized health information for pregnancy through personal health record
- general web prenatal information (Type: ACTIVE_COMPARATOR): General pregnancy health related websites

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who successfully enrolled in and completed the M04-729, (NCT00445939) study~Exclusion Criteria:~* Subject is considered by the investigator, for any reason, to be an unsuitable candidate for the study

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- DB Adalimumab 40 mg eow (Type: EXPERIMENTAL): Subjects received double-blind (DB) 40 mg adalimumab subcutaneously (SC) every other week (eow) during the DB treatment period lasting 52 weeks.
- Placebo eow (Type: PLACEBO_COMPARATOR): Subjects received placebo subcutaneously (SC) every other week (eow) during the double-blind treatment period lasting 52 weeks.
- OL Adalimumab 40 mg eow (Type: EXPERIMENTAL): Subjects received open-label (OL) 40 mg adalimumab subcutaneously (SC) every other week (eow) during the double-blind treatment period lasting 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prebiotic Treatment in People With Schizophrenia - Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. DSM-IV-TR /DSM 5 diagnosis of schizophrenia or schizoaffective disorder;~2. Age 18-60 years~3. Clinically stable as determined by opinion of treating clinician~4. Currently treated with an antipsychotic, with no dose changes in last 14 days~5. Ability to participate in the informed consent process, as determined by a score of 10 or greater on the Evaluation to Sign Consent.~6. BMI ≤ 35~Exclusion Criteria:~1. Gastrointestinal disorders, including, but not limited to Crohn's Disease, Irritable Bowel Syndrome, Celiac Disease, whose pathology or treatment could alter the presentation or treatment of schizophrenia or significantly increase the risk associated with the proposed treatment protocol~2. Organic brain disorder, including cerebrovascular accident; epilepsy; traumatic brain injury, Loss of consciousness (LOC) for more than 30 minutes~3. Intellectual disability~4. Antibiotic or immune therapy within the last three months~5. Prebiotic or probiotic treatment within the last three months~6. Inability to understand English~7. Inability to cooperate with study procedures~8. Pregnant or lactating women secondary to pregnancy~9. Meet DSM-5 criteria for alcohol or substance use disorders (except Tobacco Use Disorder) within last 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Prebiotin (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Personalized Cellular Vaccine for Brain Metastases (PERCELLVAC3)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Solid tumor with brain metastases.~* Patients at the age of 18-65.~* Patients undergo tumor resection or biopsy.~* Patients with Karnofsky scores \> or =70~* Patients with normal range of hematologic and metabolic test results.~* Patients must have no corticosteroids treatment at least one week before vaccination.~* Patients capable of understanding the study and signed informed consent.~Exclusion Criteria:~* Infectious diseases HIV, HBV, HCV.~* Documented immunodeficiency.~* Documented autoimmune disease.~* Breast feeding females.~* Pregnant women.~* Any serious or uncontrolled medical or psychiatric conditions, for example, severe pulmonary, cardiac or other systemic disease.~* Patient inability to participate as determined by PI discretion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Personalized cellular vaccine (Type: EXPERIMENTAL): Patients will undergo tumor resection or biopsy, and receive biweekly cellular vaccines consisting of mRNA-pulsed autologous DCs.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Measuring Differences in Cognition Due to Sedative Effects of Risperidone and Quetiapine in Stable Bipolar I Outpatients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with bipolar I disorder in partial or full remission and deemed clinically stable~Exclusion Criteria:~* Current use of benzodiazepines, prescription or herbal sleep agents~* Use of antihistamines~* Use of antipsychotic medications in the past 6 months~* Pregnant/breastfeeding females~* Females not using contraception~* Illicit drug users

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* glomerular filtration rate less than 30 ml / min / 1.73m~* Without replacement therapy (dialysis or hemodialysis)~* Volume overload~* At least 100 ml per day of residual diuresis~* Use of a loop diuretic for at least one month~Exclusion Criteria:~* Allergies known to diuretics~* Patients with severe infections~* Patients with hemodynamic instability~* Amputees~* Patients with cognitive impairment~* Patients with acute renal failure~* Patients with graft loss

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): This group will receive 3 milligrams of bumetanide per day for a week plus placebo (starch) that will simulate the chlorthalidone dose of the treatment group. In case the dose is well tolerated, the dose of bumetanide will be increased to 4 milligrams per day.
- Treatment grup (Type: EXPERIMENTAL): This group will receive 3 milligrams of bumetanide plus 50 milligrams of chlorthalidone per day, for a week. If the dose is well tolerated, it will be increased to 4 milligrams of bumetanide and 100 milligrams of chlorthalidone per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Effectiveness and Safety of ER OROS Paliperidone in Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have given their own consent in writing to participate in the study~* Patients diagnosed with schizophrenia according to the diagnostic criteria of DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 295.30, 295.10, 295.20, 295.90, 295.60)~* Patients who have acute symptoms of schizophrenia~* Both inpatients and outpatients are acceptable~Exclusion Criteria:~* A DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) of a mental disease diagnosis other than schizophrenia~* A DSM-IV diagnosis of substance-related disorder (except nicotine dependence and caffeine dependence) within 180 days before the screening test~* Total PANSS (Positive and Negative Syndrome System) score at the screening test \<70 or \>120~* Patients treated with three or more types of antipsychotic within 28 days before the screening test~* Parkinson's disease (except for those with drug-induced extra pyramidal symptoms)~* Patients with a complication of or a past history of cerebrovascular accident~* Patients with a complication of or a past history of diabetes mellitus

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ER OROS paliperidone (Type: EXPERIMENTAL): Extended Release (ER) Osmotic Controlled-Release Oral Delivery System (OROS) paliperidone
- Placebo (Type: PLACEBO_COMPARATOR): None
- Olanzapine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete